medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2008, Number 2

<< Back Next >>

An Med Asoc Med Hosp ABC 2008; 53 (2)

Osteoporosis: A current clinical problem

Guzmán CJ, Flores MR, Rivera PR, Suárez NE, d´ Hyver DC

Language: Spanish
References: 42
Page: 87-99
PDF size: 149.73 Kb.


ABSTRACT

Osteoporosis has become a world wide public health problem. In the United States alone it affects 4 to 6 million women. Fractures are the most frequent of complications osteoporosis presents creating a great impact on the economy and resulting in high morbimortality rate. There are diverse types of osteoporosis, which can be divided and subdivided into primary and secondary causes. The National Osteoporosis Foundation has identified risk factors in the development of osteoporosis, which have proven useful in signalling patients with a high risk. It is also useful in identifying patients who need to adjust to a new life style. The trabecular bone is the most subjected, to remodeling; it is principally found in vertebrae, the pelvis and terminals of long bones, which are the most frequently fractured. Currently, there are several pharmacological strategies to treat osteoporosis with supplements of calcium, vitamin D and biphosphonates. Within this group there is growing. Interest over zolendronic acid which in several studies has demonstrated to increase mineral bone, density and decrease in morbimortality, with minor adverse effects in comparison to biphosphonates.


REFERENCES

  1. Francis MR. Enfermedad metabólica ósea. En: Tallis CR, Fillit MH. Marban. Brocklehurst´s Geriatria. España, 2007; 871-76.

  2. Physician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation. 2003. Accessed May 4, 2007, at www.nof.org/physguide/index.htm

  3. Khosla SM, Melton JL. Osteopenia. N Engl J Med 2007; 356: 2293-3000.

  4. Montenegro SD, Pedroza NI, Vargas ES. Metabolismo óseo: Actualización. Revista de Postgrado de la VI Cátedra de Medicina 2002; 117: 116-123.

  5. Riancho JA Gutiérrez RP: Factores reguladores de la resorción Ósea. Rev Metab Oseo Min 2003; 1 (2): 51-56.

  6. Cons MF. Marcadores bioquímicos de remodelado óseo. Rev Metab Oseo Min 2003; 1 (3): 91-98.

  7. Cons MF. Marcadores bioquímicos de remodelado óseo. Rev Metab Oseo Min 2004; 2 (1): 137-147.

  8. Huerta YG, Arce SA, Casas ME. Osteoporosis inducida por corticoesteroides. Rev Metab Oseo Min 2003; 1 (2): 149-179.

  9. Roig ED, Pérez EL. Documento de consenso 2006 de la Sociedad Española de reumatología sobre la osteoporosis Postmenopáusica. Reumatol Clin 2007; supl 1: 26-32.

  10. Holick FM. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.

  11. Rose JC. Postmenopausal osteoporosis. N Engl J Med 2005; 353: 595-503.

  12. Meunier PJ, Roux C, Seaman E. The effects of strountium ranelate on the risk of vertebral fracture in woman with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-468.

  13. Canalis E, Giustina A, Bilezkain P. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007; 357: 905-909.

  14. Lee Rs, Wait R. Management of osteoporosis in postmenopausal women: 2006 position statemen of the North American Menopause Society. Menopause 2006; 13 (3): 340-365.

  15. Bone GH, Hosking D, Devogelaer PJ. Ten years´ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189-1199.

  16. Black DM, Delmas PD, Eastell R. Once – yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822.

  17. Lyles KW, Magaziner JS, Adachi JD. Zolendronic acid and clinical fractures and mortality after hip Fracture. N Engl J Med 2007; 357: 1-10.

  18. Yaffe K, Krueger K, Cummings RS. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: The multiple outcomes of raloxifene evaluation (MORE) randomized trial. Am J Psychiatry 2005; 162: 683-690.

  19. Reginster JY, Seeman E, De Vernejoul MC. Strountium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis. Treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90: 2816-2822.

  20. Seeman E, Vellas B, Benhamov C. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Boneminer Res 2006; 21: 1113-1120.

  21. McClung MR, Lewiecki EM ,Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz. Denosumab in postmenopausal women with low bone miner density. N Engl J Med 2006; 355: 821-834.

  22. Cons MF. La identificación de las fracturas vertebrales. Rev Metab Oseo Min 2004; 2 (1): 127-36.

  23. Hodsman AB, Baver DC, Larry D. Parathyroid hormone and teriparatide for treatment of osteoporosis: A review of the evidence and suggested guidelines for its use .Endocrine Reviews. 2005; 26; (5): 688-703

  24. McLean RR, Jacques FP, Selhub J. Homocysteine as predictive factor for hip fracture in older persons. N Engl J Med 2004; 350: 2042-2049.

  25. Raisz LG. Pathogenesis of osteoporosis. Concepts, conflicts and prospects. J Clin Invest 2005; 115: 3318-3325.

  26. Miller PD, Mcclung MR, Macovei L. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE Study. J Bone Miner Res 2005; 20: 1315-1322.

  27. Sambrook P, Cooper C. Osteoporosis. Lancet 2006; 367: 210-218.

  28. Delmas PD. Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civiyelli R. Intravenous ibandronate injections in postmenopausal women with osteoporosis: One year results from the Dosing Intravenous Administration Study. Arthritis Rheum 2006; 54: 1838-1846.

  29. Simon LS. Osteoporosis. Rheum Dis Clin N Am 2007; (33) 149-176.

  30. Black DM, Boones S, Cauley J, Delmas P, Eastell R, Reid I, Rosario-Jansen T, Caminis J, Zhang J, Hu H, Cummings S. Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: The HORIZON privotal fracture trial. J Bone Min Res 2006; 21 (suppl): s16.

  31. Gol M, Baris N, Guneri S, Posaci C. The effect of raloxifene on cardiac autonomic regulation in osteoporotic women. J AJOG 2006; 194: 1249-1254.

  32. McClung M. Role of rankl inhibition in osteoporosis. Arth Res Ther 2007; 9 (suppl 1): S3: 1186-2167.

  33. Virk M, Lieberman JR. Tumor metastasis to bone. Arth Res Ther 2007; 9 (suppl 1): S3: 1186-2167.

  34. Boyce BF, Xing L. Biology of RANK, RANKL and osteoprotegerin. Arth Res Ther 2007; 9 (suppl 1): S3: 1186-2167.

  35. Takayanagi H, Ogasawara K, chiba T, Murata S, Sato K. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000; 408; 600-605.

  36. Censi S, Toraldo G, Weitzmann MN, Roggia C, Gao Y, Quian WP. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 2003; 100: 10405-10410.

  37. Kotake S, Nanke Y, Mongi M, Kawamoto M, Furuya T, Yago T. IFN-gamma –producing human T cells directly induce osteoclastogénesis from human monocytes via the expression of RANKL. Eur J Immunol 2005; 35: 3353-3363.

  38. Gao Y, Quian WP, Dark K Toraldo G Lin AS, Guldberg RE. Estrogen prevents bone loss through transforming growth factor beta signaling in T cells. Proc Natl Acad Sci USA 2004; 101: 16618-16623.

  39. Toraldo G, Roggia C, Quian WP, Pacifici R, Weitzmann MN. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear kappa B ligand and tumor necrosis factor alpha from T cell. Proc Natl Acad Sci USA 2003; 100: 125-130.

  40. Rusell GR, Espina B, Hulley P. Bone biology and the pathogenesis of osteoporosis. Curr Opin Rheumatol 2006; 18 (suppl 1): S3-10.

  41. Raisz LG. Pathogenesis of osteoporosis: Concepts, conflicts and prospects. J Clin Invest 2005; 115: 3318-3325.

  42. Davies JH, Evans BA, Gregory JW. Bone mass acquisition in healthy children. Arch Dis Child 2005; 90: 373-378.




2020     |     www.medigraphic.com